Bank of New York Mellon’s Pyxis Oncology PYXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$403K Hold
133,996
﹤0.01% 3852
2026
Q1
$196K Sell
133,996
-31,048
-19% -$46.8K ﹤0.01% 4009
2025
Q4
$190K Hold
165,044
﹤0.01% 4042
2025
Q3
$366K Hold
165,044
﹤0.01% 3768
2025
Q2
$182K Sell
165,044
-107,725
-39% -$121K ﹤0.01% 4012
2025
Q1
$267K Hold
272,769
﹤0.01% 3757
2024
Q4
$426K Hold
272,769
﹤0.01% 3610
2024
Q3
$1M Sell
272,769
-38,861
-12% -$136K ﹤0.01% 3139
2024
Q2
$1.03M Buy
311,630
+149,522
+92% +$629K ﹤0.01% 3183
2024
Q1
$691K Buy
162,108
+145,974
+905% +$614K ﹤0.01% 3348
2023
Q4
$29K Buy
16,134
+2
+0% +$3 ﹤0.01% 4202
2023
Q3
$32.1K Buy
16,132
+1,649
+11% +$3.82K ﹤0.01% 4210
2023
Q2
$37.1K Buy
14,483
+715
+5% +$2.27K ﹤0.01% 4218
2023
Q1
$55.2K Buy
+13,768
New +$27.5K ﹤0.01% 4175
2022
Q2
Sell
-32,589
Closed -$132K 4677
2022
Q1
$132K Buy
32,589
+13,305
+69% +$97.3K ﹤0.01% 4345
2021
Q4
$212K Buy
+19,284
New +$221K ﹤0.01% 4258

Other funds holding PYXS

Bank of New York Mellon's PYXS Position: Q2 2026 in Review

Bank of New York Mellon held its Pyxis Oncology (PYXS) position steady in Q2 2026 at 133,996 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #3852.

Bank of New York Mellon first reported a position in PYXS in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.03M in Q2 2024. 33 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Bank of New York Mellon held 133,996 shares of Pyxis Oncology worth $403K as of Q2 2026.
  • Bank of New York Mellon left its Pyxis Oncology share count unchanged in Q2 2026.
  • Pyxis Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3852 holding.
  • Bank of New York Mellon first reported a position in Pyxis Oncology in Q4 2021 and has held it in 16 quarters since.
  • Bank of New York Mellon's Pyxis Oncology position peaked at $1.03M in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.